TCXpress™ – Rapid Delivery of clinically relevant TCRs to patients.
BlueSphere’s proprietary TCR discovery platform is a robust, high-throughput TCR identification and screening platform to enable efficient TCR discovery with a competitive timeline.
TCXpress™
TCXpress™ is a proprietary high-throughput and efficient TCR capture, expression, and functional screening platform capable of processing thousands of single T cells directly into functionally expressed TCRs within a matter of days, thereby creating extensive libraries without the need for lengthy predictive sequencing.
TCXpress™ Platform
Isolate T cells
Single Cell Sorting
and Amplification
Cloning and
Plasmid Expression
TCR
Repertoire Library
Screen
and Select
TCRs Selected for
Adoptive Cell Therapy
Isolate T cells
Single Cell Sorting
and Amplification
Cloning and
Plasmid Expression
TCR
Repertoire Library
Screen
and Select
TCRs Selected for
Adoptive Cell Therapy
Why is TCXpress™ a unique TCR discovery engine?
TCXpress™ is built upon two design innovations:
- TCRα and TCRβ chains are isolated intact and together, enabling rapid and accurate functional screening
Intact TCRs are sequenced analytically as needed, as the process does not require sequencing or gene synthesis, greatly saving on up-front costs and time
This unique discover engine allows BlueSphere to:
NEOXpress™
In addition to TCXpress, our neoantigen discovery platform, NEOXpress, can work in concert with TCXpress to screen tumor-resident TCRs for reactivity to identified neoantigens.
In this bottom-up approach, together with T-cell reporter libraries created from TCXpress™, NEOXpress™ provides the opportunity to rapidly screen and test the function of thousands of TCRs to find those specific to key neoantigens in a multiplexed way.
Tumor Sample
NeoXpress™
TcXpress™
TCRs Selected for Adoptive
Cell Therapy
Excited by our technology? Contact us, we’d love to tell you more.
